KKR's $5.7bn Integer acquisition pushes sponsors into the medtech supply chain

The most useful thing about this deal is the comp set it implies. A contract manufacturer of medical components could reasonably be priced against industrials, where multiples are sober, or against healthcare suppliers, where they are not. A sponsor paying up has picked the second comp set, and their reasoning is worth borrowing.

Regulated manufacturing carries a moat that ordinary manufacturing does not. Requalifying a supplier inside a device that already has regulatory clearance is expensive, slow, and risky for the customer. That converts a normal industrial customer relationship into something much closer to contracted revenue, and contracted revenue is what buyers pay turns for.

So the question for any components business is not 'what do manufacturers trade for'. It is 'how painful is it for my customer to replace me, and can I prove that pain with documents'. Design registrations, qualification records, sole-source letters, and tooling ownership are the evidence. Owners routinely have all four and mention none of them.

We are not moving the industrial bands on this. One large-cap transaction says something about large-cap regulated assets and very little about a $4M-EBITDA machine shop. But if you own the machine shop and half your parts are inside regulated devices, you are closer to the healthcare band than your accountant thinks.